Roxane Laboratories Launches Amlodipine Besylate Tablets

Armen Hareyan's picture
Advertisement

Amlodipine Besylate Tablets

FDA approved Roxane Laboratories' Amlodipine Besylate Tablets, 2.5mg, 5mg, and 10mg.

The product is available in bottles of 90, and the 5mg and 10mg tablets are available in bottles of 300 and Unit Dose Blisters for immediate shipment to wholesalers and pharmacies nationwide.

Advertisement

Roxane Laboratories' Amlodipine Besylate Tablets, 2.5mg, 5mg, and 10mg are AB rated to NORVASC(R) (amlodipine besylate)Tablets. Annual sales of Amlodipine Besylate Tablets, 2.5mg, 5mg, and 10mg are approximately $2.7 Billion(1).

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

Advertisement